2022 American Transplant Congress
Impact of Dysgeusia on Transplant Recipients with Refractory Cytomegalovirus with/without Resistance Receiving Maribavir: Post-Hoc Analyses from a Phase 3 Randomized Trial
*Purpose: In a Phase 3 study (SOLSTICE; NCT02931539), maribavir (MBV) was superior to investigator-assigned therapies (IAT; val/ganciclovir, foscarnet, or cidofovir) for CMV clearance at Wk…2022 American Transplant Congress
Immunoglobulin M (IgM) Inhibits Replication of SARS-CoV-2 In Vero E6 Cells In Vitro and Delays Disease in K18-hACE2 Mice Infected with SARSCoV-2 In Vivo
*Purpose: To determine if IgM has a direct effect in preventing SARS-CoV-2 replication in Vero E6 cells, and delaying or preventing disease in infected K18-hACE2…2022 American Transplant Congress
Adenosine A2A Receptor (A2AR) Agonist Apadenoson Promotes Survival in K28-hACE2 Mice and Syrian Hamsters Infected with Sars-CoV-2
*Purpose: To determine if Apadenoson or Regadenoson has a therapeutic effect in attenuating hyper-inflammation and improving survival rate in K18-hACE2mice or Syrian hamsters infected with…2022 American Transplant Congress
Metagenomic Next-Generation Sequencing Reveals the Profile of Viral Infections in Kidney Transplant Recipients During the Covid-19 Pandemic
Henan Province People's Hospital, Zhengzhou, Henan Province, China
*Purpose: To study the clinical application of metagenomic next-generation sequencing (mNGS) in the detection of viral infections in kidney transplant recipients (KTRs) during the COVID-19…2022 American Transplant Congress
Management of Hepatitis B Positive Donors in Liver Transplant
1Pharmacy, UAB, Birmingham, AL, 2UAB, Birmingham, AL
*Purpose: In an effort to expand the pool of solid organ transplant donors, patients with end stage liver disease may receive an organ from a…2022 American Transplant Congress
Transplantation of Hepatitis C Viremic Donor Organs to Hepatitis C Nonviremic Recipients: A Retrospective Review
*Purpose: The advent of combination direct-acting antiviral (DAA) agents has improved the ability to treat hepatitis C virus (HCV) infections. As a result, utilization of…2022 American Transplant Congress
Hepatitis C Positive Kidney Transplant Into Hepatitis C Negative Recipients
*Purpose: Kidney transplantation is the treatment of choice in end stage renal disease (ESRD). In 2018, 5% to 8% of eligible adults died while on…2022 American Transplant Congress
Use of Kidneys from Hepatitis C Nat Positive Donors for Uninfected Recipients: Early Results from a Rural Appalachian Kidney Transplant Program
*Purpose: Increasing mismatch between kidneys available for transplant and the number of patients on the transplant wait list has led to research into novel sources…2022 American Transplant Congress
A Randomized Phase 2 Study Of Mau868 Vs Placebo To Treat Bk Viremia In Kidney Transplant Recipients
*Purpose: To assess the safety and efficacy of MAU868, a BK virus-specific monoclonal antibody, in adult kidney transplant recipients with BK viremia.*Methods: This is a…2022 American Transplant Congress
Risk for Loss of Hepatitis B Surface Antibody or Hepatitis B Reactivation in Kidney Transplant Recipients Receiving Lymphocyte Depleting Induction
*Purpose: Although used in over 60% of kidney transplant recipients, the impact of lymphocyte depleting induction on hepatitis B surface antibody (HBsAb) and hepatitis B…
- 1
- 2
- 3
- …
- 14
- Next Page »